Premier Asset Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Premier Asset Management’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-54	Closed	-$572K	–	129
2019 Q2	$572K	Buy	+54	New	+$557K	0.13%	90
2019 Q1	–	Sell	-51	Closed	-$505K	–	127
2018 Q4	$505K	Buy	+51	New	+$713K	0.14%	94

Other funds holding GLMD

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return

Premier Asset Management's GLMD Position: Q3 2019 in Review

Premier Asset Management sold out of Galmed Pharmaceuticals (GLMD) in Q3 2019, closing a stake of 54 shares — an estimated $572K sold.

Premier Asset Management first reported a position in GLMD in Q4 2018 and held it in 2 quarters. The position peaked at $572K in Q2 2019. 26 funds tracked by Wall St. Rank hold GLMD as of Q3 2019.

Premier Asset Management reported no remaining Galmed Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Premier Asset Management sold 54 Galmed Pharmaceuticals shares in Q3 2019, an estimated $572K.
Premier Asset Management first reported a position in Galmed Pharmaceuticals in Q4 2018 and held it in 2 quarters.
Premier Asset Management's Galmed Pharmaceuticals position peaked at $572K in Q2 2019.
26 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2019.

Based on Premier Asset Management's 13F filing for Q3 2019, filed 1 Nov 2019.